Exhibit 99.1 EVAXION BIOTECH A/S INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Page Unaudited Condensed Consolidated Interim Statements of Comprehensive Loss for the Three and Six Months Ended June 30, 2023 and 2022 2 Unaudited Condensed Consolidated Interim Statements of Financial Position as of June 30, 2023 and December 31, 2022 3 Unaudited Condensed Consolidated Interim Statements of Changes in Equity for the Three and Six Months Ended June 30, 2023 and 2022 4 Unaudited Condense ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ OR ☐ SHELL COMPANY REPORT PURSUANT TO SE ...

Exhibit1.1 VEDTÆGTER / ARTICLES OF ASSOCIATION EVAXION BIOTECH A/S CVR-nr. 31762863 1. Selskabets navn og formål 1. Name and object 2. Kapitalforhold 2. Capital 2.2 Kapitalejers navn og adresse indføres i selskabets ejerbog. Ejerbogen føres af Computershare A/S (CVR-nr. 27088899). 2.3 Ingen aktie har særlige rettigheder og ingen kapitalejer er pligtig at lade sine aktier indløse. 2.3 No share carries any special rights and no shareholder is obliged to let his shares be redeemed. 2.5 Bestyrelsen er i periode ...

Evaxion Biotech A/S (EVAX) Q2 2022 Earnings Conference Call August 10, 2022 8:30 AM ET Company Participants Corey Davis - Managing Director, Investor Relations, LifeSci Advisors Lars Wegner - President and CEO Bo Karmark - Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Operator Good morning, and welcome to the Evaxion Biotech Second Quarter 2022 Earnings Call. All participants will be in a listen-only mode. [Operator Instructions] After todayÂ's presentation ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2022 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of ...

Evaxion Biotech A/S (EVAX) Q1 2022 Earnings Conference Call May 11, 2022 8:30 AM ET Company Participants Corey Davis – LifeSci Advisors Lars Wegner – Chief Executive Officer Jesper Nyegaard Nissen – Interim Chief Financial Officer Conference Call Participants Kevin DeGeeter – Oppenheimer Ahu Demir – Ladenburg Thomas Flaten – Lake Street Operator Greetings, and welcome to the Evaxion Biotech First Quarter 2022 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer sess ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ OR ☐ SHELL COMPANY REP ...

Evaxion Biotech A/S (EVAX) Q1 2021 Earnings Conference Call May 13, 2021 8:30 AM ET Company Participants Mary-Ann Chang - Investor Relations, LifeSci Advisors Lars Wegner - Chief Executive Officer Glenn Vraniak - Chief Financial Officer Conference Call Participants Kevin DeGeeter - Oppenheimer Operator Greetings. Welcome to Evaxion First Quarter 2021 Earnings Call. At this time all participants are in a listen only mode. A question-and-answer session will follow the formal presentation. [Operator Instructio ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the transition period from _________ to _________ OR ☐ SHELL COMPANY REPO ...